Wustrow I, et al. - Researchers investigated clinical outcomes consequent to aspirin omission in dual antithrombotic therapy (DAT) in a real-world group of patients receiving oral anticoagulation (OAC) therapy who were treated with a current-generation drug-eluting stent (DES) or an everolimus-eluting bioresorbable vascular scaffold (BVS). They compared outcomes between triple antithrombotic therapy (TAT) with aspirin vs DAT without aspirin in patients who had percutaneous coronary intervention (PCI) and required OAC. They found that DAT vs TAT after DES or BVS implantation was related to significantly higher rate of major adverse cardiac and cerebrovascular events.